- Home
- NGEN vs RXST Comparison
NGEN vs RXST Comparison
Compare NGEN & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGEN | RXST |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.6M | 307.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NGEN | RXST |
|---|---|---|
| Price | $4.21 | $7.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 114.9K | ★ 859.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $134,479,000.00 |
| Revenue This Year | N/A | $2.68 |
| Revenue Next Year | N/A | $10.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.73 | $6.62 |
| 52 Week High | $5.93 | $27.33 |
Technical Indicators
Market Signals| Indicator | NGEN | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 39.96 | 37.87 |
| Support Level | $3.73 | $7.06 |
| Resistance Level | $4.50 | $8.31 |
| Average True Range (ATR) | 0.25 | 0.54 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 50.00 | 29.72 |
Price Performance
Historical ComparisonAbout NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.